UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000013105
Receipt number R000015281
Scientific Title Phase 2 trial of weekly Nab paclitaxel for advanced gastric cancer patients with prior chemotherapy
Date of disclosure of the study information 2014/02/10
Last modified on 2021/08/13 17:43:34

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase 2 trial of weekly Nab paclitaxel for advanced gastric cancer patients with prior chemotherapy

Acronym

Phase 2 trial of weekly Nab paclitaxel for advanced gastric cancer patients with prior chemotherapy

Scientific Title

Phase 2 trial of weekly Nab paclitaxel for advanced gastric cancer patients with prior chemotherapy

Scientific Title:Acronym

Phase 2 trial of weekly Nab paclitaxel for advanced gastric cancer patients with prior chemotherapy

Region

Japan


Condition

Condition

advanced advanced for gastric cancer patients with prior chemotherapy

Classification by specialty

Gastroenterology Hematology and clinical oncology Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the safety and efficacy of weekly Nab paclitaxel advanced advanced for gastric cancer patients with prior chemotherapy

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Progression-free survival

Key secondary outcomes

Response Rate
Disease Contorol Rate
Overall Survival
Incidence and grade of Adverse Event,


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Nab paclitaxel(100mg/m2 day1,8,15) every 4 weeks

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

1)Patients with gastric cancer by histological or cytological examination.
2)The case that radical operation is enforced
3)Patients with prior on chemothrapy.
(including recurrence within 6 months after last adjuvant chemotherapy)
4)20 years old or more
5)ECOG performance status<=2
6)More than 2 weeks last chemotherapy
7)Patients with adequately maintained organ functions and fulfilling the following conditions within 21 days before registration
WBC count more than 3,000/mm3 less than , 12,000 /mm3
Neutrophils count more than 1,500/mm3
Hemoglobin more than 8.0 g/dl
Platelet count more than 100,000/mm3
Serum bilirubin level less than 1.5mg/dl
AST and ALT less than 2.5times
8)Patients who provided written informed consent.
9)Patients expected to survive for 90 more than days

Key exclusion criteria

1)patients previously treated with Nab-paclitaxel,paclitaxel derivative drugs
2)peripheral neuropathy
3)History of serious drug hypersensitivity
4)active synchronous malignancy with longer than 5 year interval period
5)Uncontrolled unstable angina, congestive heart failure, myocardial infarction or ventricular arrhythmia
6)Any other serious illness or medical conditions including interstitial pneumonia or pulmonary fibrosis, renal failure, liver failure,cerebrovascular disordar or Uncontrolled diabates
7)Active infection or fever suspicious of infection.
8)The case that uses a steroid regularly
9)Much amount of pleural effusion, ascites or cardiac effusion
10)Case having extensive bone metastasis
11)with brain metastasis
12)History of mental disorder, central nerve disorder
13)Pregnant women, nursing mothers
14)Patients who were considered by the primary care physician to be inappropriate for this trial

Target sample size

25


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Jiro Nagao

Organization

Toho University school of Medicine

Division name

Department of Surgery (Ohashi)

Zip code


Address

2-17-6 Ohashi, Meguro-ku, Tokyo

TEL

03-3468-1251

Email

jirojirona@med.toho-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hideaki Shimada

Organization

Toho University school of Medicine

Division name

Division of General and Gastroenterological Surgery, Department of Surgery (Omori)

Zip code


Address

6-11-1 Omori-Nishi, Ota-ku, Tokyo 143-8541, Japan

TEL

03-3762-4151

Homepage URL


Email

hideaki.shimada@med.toho-u.ac.jp


Sponsor or person

Institute

Toho University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 02 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2013 Year 11 Month 12 Day

Date of IRB

2013 Year 09 Month 19 Day

Anticipated trial start date

2014 Year 02 Month 10 Day

Last follow-up date

2016 Year 04 Month 05 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 02 Month 07 Day

Last modified on

2021 Year 08 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015281


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name